Aloe anthraquinones / PCNA Cancer Research Results

AV, Aloe anthraquinones: Click to Expand ⟱
Features:

Aloe vera — a medicinal succulent (Aloe barbadensis Miller) used as a complex botanical mixture whose clinically used preparations typically derive from (i) the inner leaf gel (polysaccharide-rich) and/or (ii) whole-leaf extracts containing anthraquinones. It is best classified as a botanical/natural product mixture (not a single agent). Common abbreviations include AV (Aloe vera). Key bioactives often discussed in oncology-adjacent literature include polysaccharides such as acemannan (immunomodulatory/wound-healing biomaterial profile) and anthraquinones such as aloe-emodin/emodin/aloin (more directly cytotoxic in vitro, but also linked to GI toxicity/carcinogenic hazard signals in certain whole-leaf preparations).

Primary mechanisms (ranked):

  1. Mitochondrial apoptosis induction in cancer models (Bax↑, Bcl-2↓, caspase activation; often attributed to anthraquinones and/or crude extracts in vitro)
  2. Inflammation and innate-immune signaling modulation (NF-κB and related cytokine axes; context-dependent, preparation-dependent)
  3. Growth/survival pathway suppression in cancer models (PI3K/AKT/mTOR and interconnected nodes; preparation-dependent)
  4. Anti-migration/anti-EMT and invasion modulation (EMT programs, MMPs; largely preclinical)
  5. Immunomodulation and tissue-repair signaling via gel polysaccharides (acemannan-driven macrophage/DC/lymphocyte activation; cytokine induction; biomaterial-like effects)
  6. Redox effects (ROS and NRF2 are preparation- and dose-dependent; antioxidant claims mainly for gel fractions, pro-oxidant/cytotoxic signaling more common with anthraquinone-rich fractions in cancer cell assays)

Bioavailability / PK relevance: Aloe preparations are heterogeneous. High–molecular-weight gel polysaccharides (e.g., acemannan) have limited systemic bioavailability and are most relevant for local mucosal/skin exposure or immune-adjacent effects; anthraquinones are more systemically absorbable but undergo metabolism and are constrained by GI tolerance and safety concerns. “Decolorized/low-anthraquinone” products differ materially from nondecolorized whole-leaf extracts.

In-vitro vs systemic exposure relevance: Many reported anticancer effects use crude extracts or isolated anthraquinones at concentrations that may exceed typical achievable systemic levels from oral supplements; supportive-care benefits (skin/mucosa) are more plausibly local exposure–driven.

Clinical evidence status: Predominantly preclinical for direct anticancer activity. Human evidence is mainly supportive-care (e.g., radiation dermatitis and oral mucositis), with mixed RCT outcomes and heterogeneous formulations; there is no high-quality evidence establishing Aloe vera as a primary anticancer therapy.

Aloe vera Therapeutic properties include: anti-microbial, anti-viral, anti-cancer, anti-oxidant, anti-inflammatory, skin protection, wound healing, and regulation of blood glucose and cholesterol.
active constituents, such as aloe-emodin and acemannan.

• Aloe vera extracts harbor antioxidant compounds that can scavenge free radicals, protecting cells from oxidative damage—a factor in aging and cancer development.

Aloe vera’s blend of bioactive compounds offers a range of biological activities—including anti-inflammatory, antioxidant, immunomodulatory, and wound-healing effects—that have attracted interest for complementary roles in health maintenance and cancer supportive care. While it is not a primary anticancer agent, its potential to mitigate treatment side effects, enhance immune responses, and possibly contribute to chemoprevention makes it a subject of ongoing research.

Aloe vera — mechanistic axes relevant to cancer and supportive care

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis program Bax↑; Bcl-2↓; caspases↑ (model-dependent) ↔ / protective (context-dependent) R/G Pro-apoptotic shift Bax↑ and Bcl-2↓ in MCF-7 with AV extract; many “direct anticancer” claims are extract- or anthraquinone-driven and preclinical.
2 PI3K/AKT/mTOR survival signaling ↓ (model-dependent) ↔ R/G Reduced growth/survival signaling Frequently reported for anthraquinones (aloe-emodin/emodin/aloin) and some crude extracts; formulation is a major confounder.
3 NF-κB inflammatory signaling ↓ (often) (context-dependent) ↓ (context-dependent) P/R Anti-inflammatory signaling shift Most relevant to supportive-care phenotypes (dermatitis/mucositis) and immune microenvironment modulation rather than direct tumor cytotoxicity.
4 Immune activation by gel polysaccharides Indirect effects via immune context Macrophage/DC activation↑; cytokines↑ R/G Immunomodulation and tissue repair support Acemannan is the best-characterized polysaccharide; systemic anticancer translation remains uncertain, but local mucosal/skin benefit is plausible.
5 ROS modulation ↑ (high concentration only) or ↓ (antioxidant fractions) ↓ (antioxidant fractions) or ↔ P/R Redox stress or scavenging Direction depends strongly on preparation: gel fractions are commonly framed as antioxidant; anthraquinone-rich fractions often act pro-oxidatively in cancer assays.
6 NRF2 antioxidant-response axis ↔ / ↑ (context-dependent) ↑ (context-dependent) G Adaptive antioxidant signaling Not consistently “primary” for AV in oncology; include as secondary because redox-adaptation can modulate therapy response and inflammation.
7 EMT, migration, invasion ↓ (model-dependent) ↔ G Reduced metastatic phenotypes Mostly preclinical; often co-reported with NF-κB/PI3K-AKT changes and MMP/EMT markers.
8 Radiosensitization or Chemosensitization ↔ (insufficient clinical proof) Radioprotection reported (context-dependent) R/G Supportive-care modulation vs sensitization Human studies more often evaluate symptom mitigation (dermatitis/mucositis) than tumor response; do not infer sensitization without direct tumor-outcome trials.
9 Clinical Translation Constraint Preparation heterogeneity; polysaccharide PK limitations; anthraquinone-driven GI effects; safety signals for nondecolorized whole-leaf extracts; evidence base mostly supportive-care — Whole-leaf (nondecolorized) extracts are classified as possibly carcinogenic to humans (IARC 2B) and produced large-intestine tumors in rodent studies; “gel-only” and decolorized/low-anthraquinone products are not equivalent.


PCNA, Proliferating Cell Nuclear Antigen: Click to Expand ⟱
Source:
Type:
Proliferating Cell Nuclear Antigen (PCNA) is a protein that plays a crucial role in DNA replication and repair. It acts as a processivity factor for DNA polymerase, helping to increase the efficiency of DNA synthesis. PCNA is also involved in various cellular processes, including cell cycle regulation, DNA damage response, and chromatin remodeling.
PCNA is often overexpressed in many types of tumors. This overexpression is associated with increased cell proliferation, which is a hallmark of cancer. The elevated levels of PCNA can serve as a biomarker for tumor growth and progression.
PCNA is called the “ringmaster of the genome” : it regulates the cell cycle and participates in DNA synthesis. PCNA is widely used as a cell proliferation marker in both healthy and malignant tissues.
Scientific Papers found: Click to Expand⟱
5362- AV,    Anti-cancer effects of aloe-emodin: a systematic review
- Review, Var, NA
AntiCan↑, eff↝, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, TumCD↑, MMP↓, ROS↑, Apoptosis↑, CDK1↓, CycB/CCNB1↓, Bcl-2↓, PCNA↓, ATP↓, ER Stress↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, MMP2↓, Ca+2↑, DNAdam↑, Akt↓, PKCδ↓, mTORC2↓, GSH↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,   TumCD↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTORC2↓, 1,  

Migration ⓘ

Ca+2↑, 1,   MMP2↓, 1,   PKCδ↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↝, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PCNA, Proliferating Cell Nuclear Antigen
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:28  Target#:489  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page